Leigh Zawel - 11 Feb 2022 Form 4 Insider Report for Cullinan Oncology, Inc. (CGEM)

Role
Chief Scientific Officer, Small Molecules
Signature
/s/ Jeffrey Trigilio, Attorney-in-Fact
Issuer symbol
CGEM
Transactions as of
11 Feb 2022
Transactions value $
$0
Form type
4
Filing time
15 Feb 2022, 15:47:15 UTC
Previous filing
18 Oct 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CGEM Common Stock Award $0 +32.5K +87.17% $0.00 69.8K 11 Feb 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CGEM Stock Option (Right to Buy) Award $0 +65K $0.00 65K 11 Feb 2022 Common Stock 65K $13.60 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the restricted stock unit vest over four years, with one forty-eighty (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.
F2 The shares underlying the option vest over four years, with one forty-eighty (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.

Remarks:

Chief Scientific Officer, Small Molecules